Chemo-Gehirn

• Literatur

• 1 Abraham J. et al. Adjuvant chemotherapy for breast cancer: Effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008; 8: 88-91.
• 2 Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy induced cognitive changes. Nat Rev Cancer 2007; 7: 192-201.
• 3 Ahles TA. et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110: 143-152.
• 4 Beltagya MEL. et al. Fluoxetine improves the mem ory deficits caused by the chemotherapy agent 5 fluorouracil. Behavioural Brain Research 2012; 208: 112-117.
• 5 Campbell K. Can exercise improve cancer associ ated cognitive dysfunction? (chemobrain) Clini calTrials.gov Identifier: NCT01296893. 2012
• 6 Cimprich B. et al. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 2010; 32: 324-331.
• 7 Correa DD, Ahles TA. Neurocognitive changes in cancer survivors. Cancer J 2008; 14: 396-400.
• 8 de Ruiter MB. et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemo therapy for breast cancer. Hum Brain Mapp 2011; 32: 1206-1219.
• 9 de Ruiter MB. et al. Late effects of high dose adju vant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp 2012; 33: 2971-2983.
• 10 Dietrich J. et al. CNS progenitor cells and oligod endrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006; 5: 22
• 11 Dietrich J. et al. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008; 13: 1285-1295.
• 12 Erickson KI. et al. Exercise training increases size of hippocampus and improves memory. PNAS 2011; 108: 3017-22.
• 13 Ernst A. et al. Neurogenesis in the striatum of the adult human brain. Cell 2014; 156: 1072-1083.
• 14 Fardell JE. et al. Chemotherapy and cognitive im pairment: treatment options. Clin Pharmacol Ther 2011; 90: 366-376.
• 15 Ferguson RJ. et al. Development of CBT for chemo therapy related cognitive change: results of a wait list control trial. Psycho Oncology 2012; 21: 176-186.
• 16 Han R. et al. Systemic 5 fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008; 7: 12
• 17 Hermelink K. et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: re sults of a prospective, multicenter, longitudinal study. Cancer 2007; 109: 1905-13.
• 18 Inagaki M. et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemother apy. Cancer 2007; 109: 146-156.
• 19 Jenkins V. et al. A 3 year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006; 94: 828-834.
• 20 Kesler SR. et al. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res 2009; 15: 6665-6673.
• 21 Kesler SR, Kent JS, O’Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 2011; 68: 1447-1453.
• 22 Lyons L. et al. Fluoxetine counteracts the cognitive and cellular effects of 5 Fluorouracil in the rat hip pocampus by a mechanism of prevention rather than recovery. PLoS ONE 2012; 7 (01) e30010. doi:10.1371/journal.pone.0030010
• 23 McDonald BC. et al. Gray matter reduction associ ated with systemic chemotherapy for breast cancer: A prospective MRI study. Breast Cancer Res Treat 2010; 123: 819-828.
• 24 McNeely ML. et al. Effects of exercise on breast cancer patients and survivors: a systematic review and meta analysis. CMAJ 2006; 175: 34-41.
• 25 Mignone RG, Weber ET. Potent inhibition of cell proliferation in the hippocampal dentate gyrus of mice by the chemotherapeutic drug thioTEPA. Brain Res 2006; 1111: 26-29.
• 26 Naylor AS. et al. Voluntary running rescues adult hippocampal neurogenesis after irradiation of the young mouse brain. PNAS 2008; 105: 14632-7.
• 27 Rodgers SP. et al. Neurogenesis, exercise, and cog nitive late effects of pediatric radiotherapy. Neural Plasticity 2013 Article ID 698528, 12 pages http://dx.doi.org/10.1155/2013/698528.
• 28 Santarelli L. et al. Requirement of hippocampal neurogenesis fort he behavioral effects of antide pressants. Science 2003; 301: 805-809.
• 29 Schagen SB. et al. Change in cognitivc function after chemotherapy: A prospective longitudinal study in breast caneer patients. J Natl Canc Inst 2006; 98: 1742-1745.
• 30 Schagen SB, Vardy J. Cognitive dysfunction in people with cancer. Lancet Oncol 2007; 8: 852-53.
• 31 Scherwath A. et al. Neuropsychological function in high risk breast cancer survivors after stem cell supported high dose therapy versus standard dose chemotherapy: evaluation of long term treatment effects. Ann Oncol 2006; 17: 415-423.
• 32 Seigers R, Fardell JE. Neurobiolgical basis of chemotherapy induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev 2011; 35: 729-741.
• 33 Seigers R. et al. Methotrexate decreases hippocam pal cell proliferation and induces memory deficits in rats. Behav Brain Res 2009; 201: 279-284.
• 34 Silverman DHS. et al. Altered frontocortical, cer ebellar, and basal ganglia activity in adjuvant treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat 2007; 103: 303-311.
• 35 Spalding KL. et al. Dynamics of hippocampal neur ogenesis in adult humans. Cell 2013; 153: 1219-27.
• 36 Spitzer M. Zwei Sprachen sind gesund! Nerven heilkunde. 2014; 33: 180-189.
• 37 Sullivan EV, Rohlfing T, Pfefferbaum A. Quanti tative fiber tracking of lateral and interhemis pheric white matter systems in normal aging: Re lations to timed performance. Neurobiol Aging 2010; 31: 464-481.
• 38 Vardy J, Rourke S, Tannock IF. Evaluation of cog nitiv function associated with chemotherapy: a re view of published studies and recommendations for future research. J Clin Oncol 2007; 25: 2455-63.
• 39 Von Ah D. et al. Putting evidence into practice: evi dence based interventions for cancer and cancer treatment related cognitive impairment. Clin J Oncol Nurs 2011; 15: 607-615.
• 40 Wefel JS. et al. The cognitive sequelae of standard dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, ran domized, longitudinal trial. Cancer 2004; 100: 2292-9.
• 41 Wefel JS. et al. Acute and late onset cognitive dys function associated with chemotherapy in women with breast cancer. Cancer 2010; 116: 3348-3356.
• 42 Wefel JS, Schagen SB. Chemotherapy related cog nitive dysfunction. Curr Neurol Neurosci Rep 2012; 12: 267-275.
• 43 Weis J, Poppelreuter M, Bartsch HH. Cognitive deficits as long term side effects of adjuvant ther apy in breast cancer patients: ‘Subjective’ com plaints and ‘objective’ neuropsychological test re sults. Psychooncology 2009; 18: 775-782.
• 44 Wong Goodrich SJE. et al. Voluntary running pre vents progressive memory decline and increases adult hippocampal neurogenesis and growth fac tor expression after whole brain irradiation. Cancer Research 2010; 70: 9329-9338.
• 45 Yoshikawa E. et al. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japan ese breast cancer survivors. Breast Canc Res Treat 2005; 92: 81-84.
• 46 Kreukels BP. et al. Effects of high dose and conven tional dose adjuvant chemotherapy on longterm cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer 2006; 7: 67-78.
• 47 Kreukels BP. et al. Electrophysiological correlates of information processing in breast cancer pa tients treated with chemotherapy. Breast Cancer Res. Treat 2005; 94: 53-61.